Brii Biosciences (FRA:7SS) Beta: 0.7953 (As of Jun. 24, 2026)


FRA:7SS Brii Biosciences Ltd FRA:7SS
33 GF Score
Price €0.10
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences Beta?

Brii Biosciences FRA:7SS -18.03% 33 Beta is 0.7953 as of Jun. 24, 2026. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Brii Biosciences's Beta is 0.7953.


Brii Biosciences  (FRA:7SS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Brii Biosciences Beta Related Terms


Brii Biosciences Beta Historical Data

* Premium members only.

The historical data trend for Brii Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brii Biosciences Beta Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.90 0.87

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.07 0.90 2.14 0.87

FRA:7SS vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Brii Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brii Biosciences Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Beta falls into.


FRA:7SS
33GF Score
Brii Biosciences Ltd FRA:7SS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7953 mean?
Brii Biosciences (FRA:7SS) has a Beta of 0.7953 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Brii Biosciences and its competitors.
Is Brii Biosciences' Beta too high?
Brii Biosciences' current Beta is 0.7953. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Beta compare to VRTX and REGN?
Brii Biosciences' Beta of 0.7953 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Brii Biosciences and its competitors. Brii Biosciences's current Beta is 0.7953. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current Beta of 0.7953. The current Beta is 0.7953. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current Beta is 0.7953 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score

Get the complete analysis for FRA:7SS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price